Diabetic Foot Treatment in Cuba: Complete Guide to Heberprot-P
Cuba's Heberprot-P is a breakthrough recombinant growth factor therapy for diabetic foot ulcers. Explore our comprehensive resources on eligibility, treatment protocol, amputation prevention, and costs.
Cuba's Pioneering Diabetic Foot Treatment
Diabetic foot ulcers are one of the most devastating complications of diabetes, affecting approximately 15% of diabetic patients during their lifetime. Without proper treatment, these ulcers can lead to serious infections and, ultimately, amputation.
Cuba developed Heberprot-P — a recombinant human epidermal growth factor (rh-EGF) injected directly into wound lesions — as a breakthrough therapy specifically designed to accelerate healing of advanced diabetic foot ulcers. This biotechnology innovation, developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, has been used to treat tens of thousands of patients.
Heberprot-P is particularly valuable for patients with ulcers that have not responded to conventional wound care. By promoting tissue regeneration at the cellular level, it offers hope to patients facing amputation.
How Heberprot-P Works
Heberprot-P contains recombinant human epidermal growth factor (rh-EGF), a protein that stimulates cell proliferation and tissue repair. When injected intra-lesionally (directly into the ulcer base), it promotes:
• Keratinocyte and fibroblast proliferation — accelerating the growth of new skin cells and connective tissue • Angiogenesis — stimulating the formation of new blood vessels to improve wound oxygenation • Granulation tissue formation — building the foundation for wound healing • Re-epithelialization — the final stage of wound closure
This targeted approach delivers the growth factor exactly where it's needed, maximizing therapeutic effect while minimizing systemic exposure. The treatment is administered on an outpatient basis over 4-6 weeks.
Complete Guide
Explore our comprehensive resources about Heberprot-P diabetic foot treatment in Cuba.
Frequently Asked Questions
What is Heberprot-P and how does it differ from conventional wound care?
Heberprot-P is a recombinant human epidermal growth factor injected directly into diabetic foot ulcers. Unlike conventional wound care (dressings, debridement, offloading), Heberprot-P actively stimulates tissue regeneration at the cellular level, promoting faster and more complete healing — particularly for ulcers that haven't responded to standard treatment.
Who is eligible for Heberprot-P treatment in Cuba?
Heberprot-P is indicated for patients with diabetic foot ulcers (Wagner grades 1-4) that have not responded to conventional treatment. Patients must have adequate vascular supply to the affected area — a vascular assessment is part of the evaluation. Your Cuban medical team will determine eligibility based on your specific condition.
How long does the treatment take?
The standard Heberprot-P protocol involves intra-lesional injections 3 times per week for 4-6 weeks, combined with comprehensive wound care. The exact duration depends on ulcer size, depth, and response to treatment. International patients should plan for a stay of 5-8 weeks in Cuba.
Begin Your Path to Healing
Submit your inquiry and our international patient coordination team will review your case and respond within 24–48 hours with a personalized treatment recommendation.
Medical Review
Our specialists evaluate your medical history and imaging
Treatment Proposal
Receive a detailed program with timeline and costs
Travel Coordination
Complete visa, accommodation, and logistics support